Singulera Therapeutics Inc design mark 50145476
"Design mark 50145476" is a figurative mark owned by Singulera Therapeutics Inc., filed at the USPTO on October 5, 2026. It is under examination and covers classes 5, 40, 42 and 44.
- Status
- Under examination
- Since October 5, 2026
- Filed
- October 5, 2026
- Registered
- Not yet
- Priority date
- September 24, 2026
- Claimed from Taiwan
- Application no.
- 50145476
- Registration no.
- Not yet
- Office
- USPTO
- United States Patent and Trademark Office
- Mark type
- Figurative mark
- 4 classes
Who owns Singulera Therapeutics Inc design mark 50145476
The owner and representative on file with the office.
Owner
Singulera Therapeutics Inc.
Chicago, United States
Representative
Angel Roman Campos
What the mark covers
The products and services Singulera Therapeutics Inc design mark 50145476 is filed for, grouped by Nice class.
Syringes sold filled with pharmaceuticals for the treatment of osteoarthritis and other degenerative joint diseases; Syringes sold filled with pharmaceuticals for chronic wound healing, including non-healing ulcers; Syringes sold filled with immune-modulating pharmaceuticals for autoimmune diseases and transplant rejection prevention; Syringes sold filled with pharmaceuticals for cardiovascular diseases, including acute myocardial infarction and ischemic conditions; Syringes sold filled with regenerative pharmaceuticals for skin and tissue repair; Organotherapy preparations; Biological preparations for use in cell cultures for medical purposes; Pharmaceutical and biological preparations for diagnostic, medical, therapeutic and prophylactic use, namely for the treatment of genetic, autoimmune and inflammatory diseases, disorders and deficiencies, and for preventing organ transplant rejection; Pharmaceutical preparations for use in treatment, amelioration and prophylaxis of diseases, disorders and suppression of the immune system; Pharmaceutical preparations for cell therapy for medical purposes; Pharmaceutical preparations for gene therapy for medical purposes; Pharmaceutical preparations for genetically modifying human and animal cells for diagnostic and medical purposes; Pharmaceutical preparations for therapies to modulate the immune system; Pharmaceutical preparations for therapeutic delivery of nucleic acids; Medical pharmaceutical preparations containing viral vectors for therapeutic and prophylactic purposes for the treatment of genetic, autoimmune and inflammatory diseases, disorders and deficiencies, and for preventing organ transplant rejection; Medical preparations containing nucleic acid vectors for therapeutic and prophylactic purposes for the treatment of genetic, autoimmune and inflammatory diseases, disorders and deficiencies, and for preventing organ transplant rejection; Stem cells for medical purposes; Opotherapy preparations; Biological reagent for medical purposes; Immunostimulants
Custom manufacturing of pharmaceuticals; Custom manufacturing of biological tissue, blood, cell and genetic material; Custom manufacturing of biological preparations; Custom biomanufacturing of pharmaceutical preparations; Custom biomanufacturing of pharmaceuticals containing cultured cells for use in cell therapy; Custom manufacturing of cell therapy preparations; Contract biomanufacturing in the field of pharmaceuticals
Biological research; Biotechnological research; Medical research; Research and development of new products for others; Technological research in the field of biotechnology; Conducting technical project studies; Industrial research in the field of biotechnology; Research and development of pharmaceutical preparations; Conducting clinical trials for others; Research and development in the field of cell therapy; Research and development in the field of biopharmaceuticals; Research and development of pharmaceutical manufacturing processes; Research and development of biopharmaceutical manufacturing processes; Testing and analysis of pharmaceutical products
Medical services; Medical and pharmaceutical consultation; Providing medical information; Stem cell therapy services; Immunotherapy services; Medical treatment services for autoimmune diseases; Medical services for the prevention and treatment of organ transplant rejection
What has happened so far
Steps recorded by the USPTO, newest first.
- Application filing receipt mailed
- New application entered
About Singulera Therapeutics Inc design mark 50145476
Who owns the trademark "Design mark 50145476"?
The USPTO trademark "Design mark 50145476" (application 50145476) is owned by Singulera Therapeutics Inc.
What is the status of "Design mark 50145476"?
Its status at the USPTO is: under examination.
Get this data via the API
Everything on this page comes from the Signa API. Pull Singulera Therapeutics Inc design mark 50145476 and marks like it into your own product with one request.
GET/v1/trademarks/{id}The full record: owners, classes, dates and images
GET/v1/trademarks/{id}/eventsEvery step in the office history
GET/v1/proceedings?trademark_id={id}Oppositions and cancellations against the mark
ID=tm_01a1115a-dc28-77de-a2b2-d090ef45fc4a
curl https://api.signa.so/v1/trademarks/$ID \
-H "Authorization: Bearer $SIGNA_API_KEY"{
"id": "tm_01a1115a-dc28-77de-a2b2-d090ef45fc4a",
"object": "trademark",
"mark_text": "[Design Mark]",
"status": {
"primary": "pending",
"stage": "examining"
},
"office_code": "US",
"application_number": "50145476",
"filing_date": "2026-10-05",
"nice_classes": [
5,
40,
42,
44
],
"owners": [
{
"name": "Singulera Therapeutics Inc.",
"entity_id": null
}
]
}